ClinicalTrials.gg
Not yet recruitingNCT07548788Updated Apr 23, 2026

A Lay Navigation Intervention for Patients With Lung Cancer

An interventional study of Care & Connect in Lung Cancer Non-Small Cell Cancer (NSCLC), Lung Cancer Small Cell Lung Cancer (SCLC) and Patient Navigation, sponsored by University Health Network, Toronto. Not yet recruiting at 1 site in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-23.

Sponsored by University Health Network, Toronto · Not applicable, Interventional, and Supportive care

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 28 studies in Carcinoma, Non-Small-Cell Lung by University Health Network, Toronto — 7 open to participants now, 10 under way, none of them phase 3. Carcinoma, Non-Small-Cell Lung · University Health Network, Toronto.

Planned enrollment
8th of 21
50 · median 38
Started
2026
with 2 others
No phase
5 of 28
1 open now
Registered
28th of 28
by date

Among the 28 studies in Carcinoma, Non-Small-Cell Lung by University Health Network, Toronto, this one is the 8th largest by planned enrollment of the 21 interventional ones that give a count, is one of 3 that started in 2026, is one of 5 with no phase, and was the 28th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

7 of the 28 studies in Carcinoma, Non-Small-Cell Lung by University Health Network, Toronto are open now, in 1 country. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Where they have run

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 28 studies in Carcinoma, Non-Small-Cell Lung by University Health Network, Toronto, or all of them as a file.
02

Study summary

Background: In Canada, lung cancer accounts for approximately 25% of cancer deaths each year. There are also known sociodemographic and racial inequities in the diagnosis and treatment of lung cancer. Studies have consistently found that patients with cancer have a high number of unmet needs, including psychological, physical, and informational. Navigation programs represent a potentially promising, equitable, and cost-effective approach to address the unmet needs of patients with lung cancer, but there is limited evidence about their effectiveness in patients with lung cancer. The investigators developed and have implemented a volunteer lay navigator program, Care and Connect (C\&C), which aims to proactively reduce distress in patients, provide information and support, and increase access to treatment and supportive care resources. The proposed pilot randomized controlled trial (RCT) project plans to 1) assess the feasibility and acceptability of referral to C\&C and, 2) examine the preliminary effectiveness of C\&C.

Methods: The current study is a 2-arm, parallel group, mixed methods, pilot RCT with a 1:1 allocation ratio and 3 timepoints: baseline (T0), 3 months (T1), 6 months (T2). It is designed to test the trial feasibility and acceptability of the C\&C intervention in patients with lung cancer. In total, 50 participants will be randomized to receive the C\&C intervention or usual care only (25 per arm). At each timepoint, data will be collected on participants' access to psychosocial (PSO) services, psychological wellbeing, and satisfaction with care through participant medical record and a survey. To gain additional insights regarding the acceptability, feasibility, and impact of C\&C, a subset of 15 participants from the intervention group will be contacted for qualitative exit interviews.

Expected outcomes: There is limited evidence about the effects of lay navigation programs on access to PSO services among patients with lung cancer. This work addresses this knowledge gap by evaluating the feasibility, acceptability, and preliminary impact of C\&C on patients with lung cancer. The findings of the proposed work will expand the body of evidence supporting lay navigation to the lung cancer population, contributing to the evidence base for patient-centred care.

03

Conditions studied

  • Lung Cancer Non-Small Cell Cancer (NSCLC)
  • Lung Cancer Small Cell Lung Cancer (SCLC)
  • Patient Navigation

Keywords

  • Lay navigation
  • Lung cancer
  • Access to care
  • Patient navigation
  • Feasibility
  • RCT
  • Pilot
  • Acceptability
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patient with diagnosis of non-small cell lung cancer (NSCLC) or small cell lung cancer (SCLC) of any stage
  • Age ≥ 18
  • Have completed their first medical appointment at the Medical Oncology Lung Cancer Clinic at Princess Margaret Cancer Centre (PM), University Health Network
  • Cognitive capacity to consent and complete questionnaires

Exclusion criteria

Exclusion Criteria:

  • Behavioural safety alert on medical record that would make their participation in Care \& Connect inappropriate
  • Enrolment in another navigation study within University Health Network
  • Patients who come to PM for a clinical trial visit
  • Inability to communicate and read in English
05

Study design

Phase
Not applicable
Primary purpose
Supportive care
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Intervention Group

    Participants in the intervention group receive Care \& Connect (C\&C), a 6-month lay navigation program, in addition to usual care. Trained lay navigators provide psychosocial and informational support and assist with health system navigation, including directing patients to appropriate resources, facilitating referrals to psychosocial services as appropriate, and connecting participants with relevant hospital and community resources.

    Behavioral: Care & Connect

  • No intervention
    Usual Care

    Participants in the control group receive usual care, including routine treatment and follow up in outpatient oncology clinics. Usual care includes distress screening (whereby patients are invited to complete the Edmonton Symptom Assessment System-Revised as part of clinic visits), with results reviewed by clinic staff and communicated to oncologists for further assessment and referral to specialized services as needed. Participants may also be referred to specialized services based on clinical judgement or patient request and have access to standard informational and educational resources available through the hospital.

Interventions

  • BehavioralCare & Connect

    6-month lay navigation program. Lay navigators provide basic psychosocial and informational support and health system navigation through phone call or video conference. Sessions held with patients are variable based on patients' needs.

06

What researchers measure

Primary outcomes

  1. Feasibility Assessed by Recruitment Rates

    ≥50% recruitment rate (#patients consented/ #patients eligible and approached)

    Time frame: From study start date to the end of treatment at 6 months

  2. Feasibility Assessed by Questionnaire Completion

    ≥80% baseline questionnaire completion rate (#patients who complete baseline questionnaire/ #patients consented)

    Time frame: From study start date to the end of treatment at 6 months

  3. Feasibility Assessed by Questionnaire Completion

    ≥65% questionnaire completion rate at follow-up (i.e., 3- and 6-months) (#patients who complete each follow-up questionnaire/ #patients matched with a navigator or #patients who complete each follow-up questionnaire/ #patients randomized to the control group)

    Time frame: From study start date to the end of treatment at 6 months

  4. Feasibility Assessed by Protocol Adherence

    ≥65% of patients completing at least 1 session with a lay navigator

    Time frame: From study start date to the end of treatment at 6 months

  5. Acceptability

    Intervention acceptability will be assessed using the Patient Satisfaction with Navigator-Interpersonal Relationship scale (PSN-I), a 9-item self-report measure of patients' satisfaction with the relationship with their navigator. Higher PSN-I scores indicate greater patient satisfaction. Acceptability is defined as ≥70% of participants scoring ≥30 on the PSN-I.

    Time frame: This measure will be administered at 3 months and 6 months

Secondary outcomes

  1. Referral of Care to Psychosocial Oncology Services

    This outcome is operationalized as the proportion of patients and patient's number of sessions of specialized Psychosocial Oncology (PSO) services within the hospital setting during the study period. Data regarding PSO services use will be collected from participants' medical record.

    Time frame: From study start date to the end of treatment at 6 months

  2. Referral of Care to Palliative Services

    This outcome is operationalized as the proportion of patients and patient's number of sessions of specialized palliative care within the hospital setting during the study period. Data regarding palliative care use will be collected from participants' medical record.

    Time frame: From study start date to the end of treatment at 6 months

  3. Depressive symptoms using the PHQ-9

    Depressive symptoms will be assessed using the Patient Health Questionnaire-9 (PHQ-9). The PHQ-9 is a 9-item measure of depression. A four-point Likert scale scores from 0 (not at all) to 3 (nearly every day), with a total score ranging from 0 to 27. Higher scores are related to higher depression severity.

    Time frame: This measure will be administered at baseline, 3 months and 6 months

  4. Generalized anxiety symptoms using the GAD-7

    Generalized anxiety will be assessed using the Generalized Anxiety Disorder scale (GAD-7). The GAD-7 is a 7-item self-report measure designed to screen the severity of GAD symptoms. Items are scored on a four-point Likert scale ranging from 0 (not at all) to 3 (nearly every day) with a total score ranging from 0 to 21. Scores from 0-4 indicate minimal anxiety, 5-9 indicate mild anxiety, 10-14 indicate moderate anxiety, and 15-21 indicate severe anxiety.

    Time frame: This measure will be administered at baseline, 3 months and 6 months

  5. Distress about death and dying symptoms using the DADDS

    Distress about death and dying will be assessed using the Death and Dying Distress Scale (DADDS). The DADDS is a 15-item self-report measure assessing specific concerns of advanced cancer patients about end of life, feeling a burden to others and wasted opportunities. It is scored on a six-point Likert scale from 0 (no distress) to 5 (very much distress), with a total score ranging from 0 to 75, a greater score indicating higher death anxiety and distress.

    Time frame: This measure will be administered at baseline, 3 months and 6 months

  6. Patient satisfaction with cancer care using the PSCC

    Patient satisfaction with cancer care will be measured with the Patient Satisfaction with Cancer-Related Care Measure (PSCC). The PSCC is an 18-item questionnaire that addresses multiple domains, including: access/logistics, interpersonal skills of the provider, information gathering and reporting, and coordination of care. PSCC items are rated on 5-point Likert scales: "1 = Strongly Agree", "2 = Agree", "3 = Neutral", "4 = Disagree", and "5 = Strongly Disagree". A lower PSCC total score indicates higher satisfaction level. The PSCC questionnaire has a score range between a minimum of 18 (best score) and a maximum of 90 (worst score).

    Time frame: This measure will be administered at baseline, 3 months and 6 months

  7. Patient satisfaction with cancer care using the CEQ-INS

    Patient satisfaction with cancer care will be measured with the Clinical Evaluation Questionnaire-Information Navigation and Support (CEQ-INS). CEQ-INS is a 19-item self-reported instrument with questions used 4-point Likert scale (1 'Not at All' to 4 'Very Much'). Higher scores correlate with higher patient satisfaction with the information and support provided from their care team.

    Time frame: This measure will be administered at baseline, 3 months and 6 months

Other outcomes

  1. Health related quality of life using the FACT-G

    HRQoL will be assessed with the Functional Assessment of Cancer Therapy - General (FACT-G). The FACT-G is a 27-item questionnaire that covers four HR-QOL sub-domains: physical, social, emotional, and functional well-being. Each of the questions will be scored on a scale from 0 (Not at all) to 4 (Very much) using a manual scoring template in which some items are reverse scored. The minimally important difference (MID) is 5 points for the FACT-G questionnaire. In other words, five points is the most minimal difference between the control group and treatment group scores that would indicate a clinically meaningful change. A positive change in points indicates better QOL.

    Time frame: This measure will be administered at baseline, 3 months and 6 months

  2. Perceived social support using the ESSI

    Perceived social support will be measured using the ENRICHD Social Support Instrument (ESSI). ESSI is a 7-item scale used to measure perceived social support. The first six items have a rating scale of 1 (none of the time) to 5 (all of the time) and the seventh is scored 4 for 'yes' and 2 for 'no'. Total scores range from 8 to 34. A lower total score reflects less support.

    Time frame: This measure will be administered at baseline, 3 months and 6 months

  3. Patient activation using the PAM-13

    Patient activation will be measured using the Patient Activation Measure-13 items (PAM-13). The PAM-13 measures patient activation through self-reports of knowledge, skills, and confidence related to self-management of one's own health care. This 13-item self-report assesses confidence in self-management and understanding of health condition. Each of the 13 items scored on a 5-point Likert scale. The primary outcome is an activation score derived from the 13 items (possible range of 0-100, higher scores indicating higher patient activation in self-management).

    Time frame: This measure will be administered at baseline, 3 months and 6 months

  4. Access to psychosocial services outside of the hospital

    This includes the number, duration, and date of psychosocial appointments that are received outside of the hospital setting during the study period. This will be self-reported by participants.

    Time frame: From study start date to the end of treatment at 6 months

  5. Healthcare utilization using the Health Care Utilization Questionnaire

    Healthcare utilization will be measured using the Health Care Utilization Questionnaire. The Health Care Utilization Questionnaire is a 12 item self-report instrument designed to capture participants' use of healthcare services during the study period. Responses are recorded as counts of service use and will be used to estimate overall healthcare utilization during the study period, with higher values indicating greater use of healthcare services.

    Time frame: This measure will be administered at baseline, 3 months and 6 months

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Apr 2026; primary completion for Jun 2027, 14 months later.

Of 345 non-industry interventional studies with no phase under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 52 months of starting (the median), counting those still running; a quarter within 28 and three quarters within 97. This study's planned 14 months is below that.

Counting every sponsor, half of 361 studies reached it within 51 months; a quarter within 26 and three quarters within 97.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 14, 2026
First posted
Apr 23, 2026
StartEst.
Apr 1, 2026
Primary completionEst.
Jun 1, 2027
CompletionEst.
Dec 1, 2027
Last update
Apr 23, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 23, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07548788
Responsible party
Gilla Shapiro (Clinician Scientist, University Health Network, Toronto) — Principal investigator
First posted
Apr 23, 2026
Start date
Apr 1, 2026 (estimated)
Primary completion
Jun 1, 2027 (estimated)
Completion
Dec 1, 2027 (estimated)
Last update
Apr 23, 2026

Study contacts

Gilla K Shapiro, PhD
Contact
gilla.shapiro@uhn.ca
416-946-4501 ext.4211
Research Coordinator
Contact
CACResearch@uhn.ca
Gilla K Shapiro, PhD
principal investigator · Princess Margaret Cancer Centre, University Health Network
Gary Rodin, MD
principal investigator · Princess Margaret Cancer Centre, University Health Network

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion